ORIC PHARMACEUTICALS, INC. Gain (Loss) on Disposition of Assets
ORIC PHARMACEUTICALS, INC. (ORIC) reported Gain (Loss) on Disposition of Assets of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-18.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2025-02-18
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2024-12-31 was $0.00.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2024-09-30 was $0.00.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2023-12-31 was -$13.00K.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2023-09-30 was $0.00.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2024 was $0.00.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2023 was -$22.00K.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2022 was -$40.00K.
- ORIC PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2021 was -$2.00K.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $0.00 10-K · filed 2025-02-18 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 | |||
| 2023-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$13.00K derived: sum of 2 quarters · filed 2025-02-18 | -$22.00K 10-K · filed 2025-02-18 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$9.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$9.00K 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$40.00K derived: sum of 2 quarters · filed 2024-03-11 | -$40.00K 10-K · filed 2024-03-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.00K derived: sum of 2 quarters · filed 2023-03-16 | -$2.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$2.00K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | -$3.00K 10-Q · filed 2022-08-11 | |||
| 2019-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$5.00K derived: sum of 2 quarters · filed 2022-03-21 | -$8.00K 10-K · filed 2022-03-21 | |
| 2019-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$7.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$3.00K 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | -$15.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |